8129
TOHO HOLDINGS CO.,LTD.
東邦ホールディングス株式会社
Wholesale Trade
Toho Holdings Co., Ltd. engages in the wholesale distribution of pharmaceutical products in Japan. It operates in four segments: Pharmaceutical Wholesale Business, Dispensing Pharmacy Business, Pharmaceutical Manufacturing and Sales Business, and Other Peripheral Businesses. The company sells pharmaceuticals, narcotics, reagents, and medical devices to hospitals, clinics, and dispensing pharmacies. It is also involved in the management of the dispensing pharmacies business; operates health insurance pharmacy; provision of support home medical care services; peripheral businesses; core system operations; and real estate agency business. In addition, the company manufacture and sell pharmaceuticals; sells generic drugs; and manufactures injection drugs on consignment. Further, it provides support services, including the development and sale of customer support systems, assistance in the start-up of medical institutions and pharmacies, management consulting services, medical support, and personnel recruitment. Additionally, the company offers various customer support systems, including ENIF, an information terminal for pharmaceutical ordering; ENI-Pharmacy, a support system for the separation of dispensing and prescribing functions; LXMATE Helios a medical care appointment system; KAITOS, an online medical consultation and medication guidance system; ENIFwin Nex-Sus, an inventory control system for large hospitals ENIFvoice SP/ ENIFvoice SP + A/ ENIFvoice Core, a supporting system for electronic medication history recording with voice recognition. The company was incorporated in 1948 and is headquartered in Chuo, Japan.
Price
¥4,217
Market Cap
¥263.9B
Ent. Value
¥196.6B
Net Cash
¥67.3B
Shares Out.
62.6M
P / E
13.5×
EV / EBIT
0.1×
P / Book
1.03×
P / NCAV
3.18×
Div. Yield
1.54%
Financials
| Metric |
FY 2025
TDnet |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Net Sales | ¥1,572.0B | ¥1,518.5B | ¥1,476.7B | ¥1,388.6B | ¥1,266.2B |
| Cost of Sales | — | ¥1,396.8B | ¥1,357.6B | ¥1,277.8B | ¥1,157.5B |
| Gross Profit | — | ¥121.6B | ¥119.1B | ¥110.8B | ¥108.7B |
| SG&A | — | ¥102.7B | ¥99.8B | ¥98.0B | ¥96.2B |
| Operating Income | ¥1,572.0B | ¥18.9B | ¥19.3B | ¥12.8B | ¥12.5B |
| Non-Operating Income | — | ¥2.6B | ¥3.2B | ¥6.9B | ¥6.2B |
| Dividend Income | — | ¥1.1B | ¥1.2B | ¥1.3B | ¥1.4B |
| Interest Income | — | ¥93M | ¥58M | ¥58M | ¥64M |
| Non-Operating Expenses | — | ¥866M | ¥771M | ¥502M | ¥551M |
| Interest Expense | — | ¥46M | ¥62M | ¥72M | ¥76M |
| Ordinary Income | ¥1,572.0B | ¥20.7B | ¥21.8B | ¥19.2B | ¥18.2B |
| Pre-tax Income | — | ¥28.1B | ¥30.8B | ¥20.4B | ¥20.1B |
| Income Taxes | — | ¥8.2B | ¥10.1B | ¥6.8B | ¥6.7B |
| Current Tax | — | ¥9.1B | ¥10.9B | ¥7.8B | ¥7.2B |
| Deferred Tax | — | ¥-892M | ¥-808M | ¥-1.0B | ¥-484M |
| Net Income (owners) | ¥15.7B | ¥19.8B | ¥20.7B | ¥13.6B | ¥13.4B |
| Minority Interest | — | ¥12M | ¥12M | ¥19M | ¥35M |
| Comprehensive Income | — | ¥16.2B | ¥20.7B | ¥11.6B | ¥5.7B |
| EBITDA | — | ¥25.0B | ¥25.8B | ¥19.2B | ¥19.5B |
| Goodwill Amort. (J-GAAP) | — | ¥150M | ¥270M | ¥294M | ¥323M |
| EPS | — | ¥313.20 | ¥320.14 | ¥196.70 | ¥189.70 |
| Shares Outstanding | — | 62.6M | 62.8M | 66.9M | 70.5M |
| Shares Issued (total) | — | 73.0M | 76.4M | 78.3M | 78.3M |
| Treasury Shares | — | 10.4M | 13.7M | 11.3M | 7.8M |
| Metric |
FY 2025
TDnet |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | — | ¥722.8B | ¥773.4B | ¥715.3B | ¥702.4B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current Assets | — | ¥548.9B | ¥597.9B | ¥533.5B | ¥513.1B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Deposits | — | ¥86.5B | ¥133.0B | ¥86.2B | ¥94.3B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trade Receivables | — | ¥330.7B | ¥336.6B | ¥313.9B | ¥299.4B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-Current Assets | — | ¥173.9B | ¥175.5B | ¥181.8B | ¥189.3B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PP&E | — | ¥86.8B | ¥87.5B | ¥90.3B | ¥94.7B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill | — | ¥193M | ¥297M | ¥514M | ¥733M | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets | — | ¥6.1B | ¥5.6B | ¥5.4B | ¥5.2B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment Securities | — | ¥64.1B | ¥70.2B | ¥72.6B | ¥78.7B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred Tax Assets | — | ¥3.3B | ¥2.1B | ¥2.1B | ¥2.0B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | — | ¥465.9B | ¥524.0B | ¥472.4B | ¥461.1B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current Liabilities | — | ¥424.0B | ¥471.3B | ¥440.2B | ¥402.8B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable | — | ¥397.7B | ¥438.1B | ¥385.1B | ¥370.0B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ST Debt | — | ¥1.7B | ¥552M | ¥9.8B | ¥6.5B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Taxes Payable | — | ¥5.9B | ¥7.4B | ¥5.2B | ¥5.4B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-Current Liabilities | — | ¥41.9B | ¥52.7B | ¥32.2B | ¥58.3B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total LT Borrowings | — | ¥17.6B | ¥28.2B | ¥6.5B | ¥32.6B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pension Obligations | — | ¥2.8B | ¥2.5B | ¥2.5B | ¥2.4B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred Tax Liab. | — | ¥10.6B | ¥11.7B | ¥12.4B | ¥14.2B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | — | ¥256.9B | ¥249.4B | ¥242.9B | ¥241.3B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Stock | — | ¥10.6B | ¥10.6B | ¥10.6B | ¥10.6B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Surplus | — | ¥45.2B | ¥45.2B | ¥49.1B | ¥49.2B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Retained Earnings | — | ¥218.9B | ¥209.7B | ¥191.5B | ¥180.3B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treasury Stock | — | ¥-28.8B | ¥-30.9B | ¥-23.1B | ¥-15.7B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AOCI | — | ¥10.7B | ¥14.5B | ¥14.5B | ¥16.5B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity (owners) | — | ¥246.0B | ¥234.7B | ¥228.2B | ¥224.4B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Minority Interests | — | ¥116M | ¥104M | ¥92M | ¥199M | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Interest-Bearing Debt ⓘ | — | ¥19.3B | ¥28.7B | ¥16.3B | ¥39.2B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Cash ⓘ | — | ¥67.3B | ¥104.3B | ¥69.9B | ¥55.1B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| NCAV ⓘ | — | ¥83.0B | ¥73.9B | ¥61.1B | ¥52.0B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| NCAV/Share | — | ¥1,327 | ¥1,178 | ¥913 | ¥738 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BV/Share | — | ¥3,931 | ¥3,740 | ¥3,409 | ¥3,182 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Metric |
FY 2025
TDnet |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Operating CF | — | ¥-26.7B | ¥59.9B | ¥-9M | ¥16.3B |
| Interest Paid | — | ¥-47M | ¥-62M | ¥-71M | ¥-78M |
| Interest Received | — | ¥1.1B | ¥1.3B | ¥1.3B | ¥1.5B |
| D&A | — | ¥5.9B | ¥6.2B | ¥6.1B | ¥6.6B |
| Goodwill Amort. | — | ¥150M | ¥270M | ¥294M | ¥323M |
| Investing CF | — | ¥-4.2B | ¥9.1B | ¥4.3B | ¥-11.0B |
| CapEx | — | ¥4.1B | ¥2.5B | ¥1.6B | ¥3.6B |
| Purchase Investments | — | ¥-1.5B | ¥-2.1B | ¥-445M | ¥-1.1B |
| Financing CF | — | ¥-20.4B | ¥-22.2B | ¥-13.1B | ¥-4.5B |
| Dividends Paid | — | ¥-3.0B | ¥-2.2B | ¥-2.2B | ¥-2.1B |
| Share Buybacks | — | ¥-15.0B | ¥-12.0B | ¥-7.4B | ¥0M |
| LT Debt Repaid | — | ¥-413M | ¥-9.6B | ¥-6.4B | ¥-2.8B |
| Free Cash Flow | — | ¥-30.7B | ¥57.4B | ¥-1.6B | ¥12.7B |
| Net Change in Cash | — | ¥-51.2B | ¥46.8B | ¥-8.8B | ¥835M |
| Metric |
FY 2025
TDnet |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| ROE | — | 7.8% | 8.4% | 5.6% | 5.6% |
| ROA | — | 2.7% | 2.8% | 1.9% | 1.9% |
| EPS | — | ¥313.20 | ¥320.14 | ¥196.70 | ¥189.70 |
| DPS | — | ¥65.00 | ¥40.00 | ¥32.00 | ¥30.00 |
| BPS | — | ¥4,099.71 | ¥3,969.20 | ¥3,623.81 | ¥3,415.50 |
| FCF/Share | — | ¥-491 | ¥915 | ¥-25 | ¥180 |
| NCAV/Share | — | ¥1,327 | ¥1,178 | ¥913 | ¥738 |
| Payout Ratio | — | 20.8% | 12.5% | 16.3% | 15.8% |
Event Timeline
S Shareholder
A Capital Signal
Large Shareholder Reports 37
| # | Shareholder | Shares (thou.) | % of Total |
|---|---|---|---|
| 1 | STATE STREET BANK AND TRUST COMPANY 505018(常任代理人 株式会社みずほ銀行決済営業部) | 9,646 | 15.41% |
| 2 |
The Master Trust Bank of Japan, Ltd. (Trust Account)
日本マスタートラスト信託銀行株式会社(信託口)
|
6,059 | 9.68% |
| 3 |
Shionogi & Co.,Ltd.
塩野義製薬株式会社
|
3,500 | 5.59% |
| 4 | 3D WH OPPORTUNITY MASTER OFC - 3D WH OPPORTUNITY HOLDINGS(常任代理人 株式会社みずほ銀行決済営業部) | 2,400 | 3.83% |
| 5 |
Japan Custody Bank
株式会社日本カストディ銀行(信託口)
|
1,494 | 2.39% |
| 6 | 河野 博行 | 1,333 | 2.13% |
| 7 |
Custody Bank of Japan, Ltd. (Trust Account)
みずほ信託銀行株式会社 退職給付信託 第一三共口 再信託受託者 株式会社日本カストディ銀行
|
1,328 | 2.12% |
| 8 |
Employee Stock Ownership Plan
東邦ホールディングス従業員持株会
|
1,310 | 2.09% |
| 9 |
Mizuho Securities
みずほ証券株式会社
|
1,282 | 2.05% |
| 10 | STATE STREET BANK AND TRUST COMPANY 505103(常任代理人 株式会社みずほ銀行決済営業部) | 1,231 | 1.97% |
as of 2025-03-31
Source: EDINET ↗
Ownership by year — hover bars for detail
Domestic Nominees
14.2%
-1.5% vs 2024
Trust bank custodians — GPIF, pensions, investment trusts
Foreign Custodians
0.0%
+0.0% vs 2024
Sub-custodians for foreign asset managers
Direct / Strategic
33.1%
+13.4% vs 2024
Named entities with disclosed investment intent
Bar = % of shares outstanding · top-10 covers 47.3% · grey = other shareholders · 2025
| Shareholder | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| STATE STREET BANK AND TRUST COMPANY 505018 NEW ENTRY | — | — | — | 15.41% NEW |
| Japan Master Trust Bank 日本マスタートラスト信託銀行 | 11.75% | 10.06% | 9.68% -0.38% | |
| Shionogi & Co.,Ltd. 塩野義製薬 | 5.23% | 5.57% | 5.59% +0.02% | |
| Japan Custody Bank 日本カストディ銀行 | 7.95% | 5.64% | 4.51% -1.13% | |
| 3D WH OPPORTUNITY MASTER OFC - 3D WH OPPORTUNITY HOLDINGS NEW ENTRY | — | — | — | 3.83% NEW |
| 河野 博行 | 1.99% | 2.12% | 2.13% +0.01% | |
| Employee Stock Ownership Plan 東邦ホールディングス従業員持株会 | 2.55% | 2.44% | 2.09% -0.35% | |
| Mizuho Securities みずほ証券 | — | 2.43% | 2.05% -0.38% | |
| STATE STREET BANK AND TRUST COMPANY 505103 NEW ENTRY | — | — | — | 1.97% NEW |
| BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC) BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC) last seen 2024 | Exited Top 10 | — | 3.03% | — |
| BNP PARIBAS FINANCIAL MARKETS BNP PARIBAS FINANCIAL MARKETS last seen 2024 | Exited Top 10 | — | 2.08% | — |
| JPモルガン証券 last seen 2024 | Exited Top 10 | — | 2.02% | — |
| SSBTC CLIENT OMNIBUS ACCOUNT last seen 2023 | Exited Top 10 | 2.20% | — | — |
| 第一三共 last seen 2023 | Exited Top 10 | 1.63% | — | — |
| GOLDMAN SACHS INTERNATIONAL last seen 2023 | Exited Top 10 | 2.33% | — | — |
| MLI FOR CLIENT GENERAL OMNI NON COLLATERAL NON TREATY-PB last seen 2023 | Exited Top 10 | 1.88% | — | — |
| Concentration (HHI) ⓘ | 256 | 198 | 414 |
3 fiscal years · top-10 holders per year · >2,500 HHI = high concentration · entity-resolved
Portfolio Book Value
¥32,650M
-23% since 2023
Holdings
43
+2 new
8 exited
Trend
3 unwinding
vs 2023
| Held Company | FY2025 ¥32,650M total | FY2023 ¥42,545M total | |||
|---|---|---|---|---|---|
| Book Val ¥M | Shares | Book Val ¥M | Shares | ||
|
Otsuka Holdings Co., Ltd.
大塚ホールディングス㈱
|
15,506 |
-53.2%
↓
2,000,000
|
17,949 | 4,270,640 | M |
|
Shionogi & Co.,Ltd.
塩野義製薬㈱
|
3,528 |
+200.0%
↑
1,570,842
|
3,129 | 523,614 | M |
|
Solasto Corporation
㈱ソラスト
|
2,156 |
4,709,500
|
2,985 | 4,709,500 | |
|
ONO PHARMACEUTICAL CO., LTD.
小野薬品工業㈱
|
1,887 |
1,177,920
|
3,255 | 1,177,920 | M |
|
DAIICHI SANKYO COMPANY, LIMITED
第一三共 ㈱
|
1,842 |
NEW
New
524,900
|
— | M | |
|
螟ァ譛ィ繝倥Ν繧ケ繧ア繧「繝帙�シ繝ォ繝�繧」繝ウ繧ー繧ケ譬ェ蠑丈シ夂、セ
大木ヘルスケアホールディングス㈱
|
1,131 |
1,413,000
|
1,147 | 1,413,000 | M |
|
TSUMURA & CO.
㈱ツムラ
|
980 |
-65.3%
↓
227,300
|
1,721 | 654,600 | M |
|
TERUMO CORPORATION
テルモ㈱
|
944 |
-40.6%
↓
337,800
|
2,033 | 568,900 | M |
|
SANTEN PHARMACEUTICAL CO.,LTD.
参天製薬㈱
|
805 |
567,950
|
641 | 567,950 | M |
|
Meiji Holdings Co., Ltd.
明治ホールディングス㈱
|
528 |
+101.2%
↑
162,481
|
509 | 80,750 | M |
|
Medical Ikkou Group Co.,Ltd.
㈱メディカル一光グループ
|
474 |
203,000
|
489 | 203,000 | |
|
HISAMITSU PHARMACEUTICAL CO.,INC.
久光製薬㈱
|
378 |
+9.5%
↑
93,581
|
323 | 85,460 | M |
|
KISSEI PHARMACEUTICAL CO.,LTD.
キッセイ薬品工業㈱
|
377 |
+9.2%
↑
98,176
|
237 | 89,885 | M |
|
Nippon Shinyaku Co.,Ltd.
日本新薬㈱
|
368 |
96,959
|
565 | 96,959 | M |
|
KYORIN Pharmaceutical Co., Ltd.
杏林製薬㈱
|
307 |
NEW
New
205,000
|
— | M | |
|
Mochida Pharmaceutical Co.,Ltd.
持田製薬㈱
|
281 |
88,468
|
295 | 88,468 | M |
|
ZERIA PHARMCEUTICAL CO., LTD.
ゼリア新薬工業㈱
|
228 |
101,374
|
227 | 101,374 | M |
|
Advanced Media, Inc.
㈱アドバンスト・メディア
|
140 |
162,000
|
288 | 162,000 | |
|
WELCIA HOLDINGS CO., LTD.
ウエルシアホールディングス㈱
|
132 |
+11.9%
↑
61,461
|
155 | 54,927 | |
|
Fuso Pharmaceutical Industries,Ltd.
扶桑薬品工業㈱
|
97 |
40,083
|
80 | 40,083 | M |
|
KOBAYASHI PHARMACEUTICAL CO.,LTD.
小林製薬㈱
|
94 |
+2.2%
↑
16,615
|
131 | 16,258 | M |
|
SYSMEX CORPORATION
シスメックス㈱
|
91 |
+200.0%
↑
32,400
|
93 | 10,800 | |
|
Hokuyaku Takeyama Holdings Co., Ltd.
㈱ほくやく・竹山ホールディングス
|
89 |
100,766
|
63 | 100,766 | M |
|
Kringle Pharma,Inc.
クリングルファーマ㈱
|
58 |
66,660
|
64 | 66,660 | |
|
Sumitomo Pharma Co., Ltd.
住友ファーマ㈱
|
56 |
77,086
|
62 | 77,086 | M |
|
SHIP HEALTHCARE HOLDINGS, INC.
シップヘルスケアホールディングス㈱
|
40 |
20,000
|
48 | 20,000 | |
|
BML, INC.
㈱ビー・エム・エル
|
39 |
13,000
|
40 | 13,000 | |
|
Eisai Co., Ltd.
エーザイ㈱
|
38 |
9,300
|
69 | 9,300 | |
|
KAKEN PHARMACEUTIAL CO., LTD.
科研製薬㈱
|
29 |
6,567
|
24 | 6,567 | M |
| ㈱ジェイ・エム・エス | 21 |
+15.1%
↑
45,786
|
20 | 39,796 | |
|
NIPPON CHEMIPHAR CO., LTD.
日本ケミファ㈱
|
6 |
4,329
|
7 | 4,329 | M |
|
SAPPORO HOLDINGS LIMITED
サッポロホールディングス㈱
|
— | — | |||
|
AEON Co.,Ltd.
㈱イオン
|
— | — | |||
|
AEON Co.,Ltd.
イオン㈱
|
— | — | |||
|
Mitsubishi Chemical Gloup Corporation
三菱ケミカルグループ㈱
|
— | — | |||
|
Nichi-Iko Pharmaceutical Co.
日医工㈱
|
— | — | M | ||
|
CHUGAI PHARMACEUTICAL CO., LTD.
中外製薬㈱
|
— | — | |||
|
Tokio Marine Holdings, Inc.
東京海上ホールディングス㈱
|
— | — | M | ||
|
Mizuho Financial Group, Inc.
㈱みずほフィナンシャルグループ
|
— | — | M | ||
|
Sumitomo Mitsui Financial Group, Inc.
㈱三井住友フィナンシャルグループ
|
— | — | M | ||
| 日水製薬㈱ | — | — | |||
|
Nipro Co., Ltd.
ニプロ㈱
|
— | — | |||
|
Nomura Holdings Inc.
野村ホールディングス㈱
|
— | — | M | ||
|
SUZUKEN CO.,LTD.
㈱スズケン
|
— |
−100%
Exit
—
|
34 | 10,249 | M |
|
MEDIPAL HOLDINGS CORPORATION
㈱メディパルホールディングス
|
— |
−100%
Exit
—
|
71 | 39,361 | M |
|
Alfresa Holdings Corporation
アルフレッサホールディングス㈱
|
— |
−100%
Exit
—
|
5 | 3,000 | M |
|
DAIICHI SANKYO COMPANY, LIMITED
第一三共㈱
|
— |
−100%
Exit
—
|
5,231 | 1,084,896 | M |
| キョーリン製薬ホールディングス㈱(注3) | — |
−100%
Exit
—
|
349 | 205,000 | M |
|
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
大正製薬ホールディングス㈱
|
— |
−100%
Exit
—
|
135 | 24,521 | M |
|
YAKULT HONSHA CO.,LTD.
㈱ヤクルト本社
|
— |
−100%
Exit
—
|
70 | 7,300 | M |
|
Vital KSK Holdings Co., Ltd.
㈱バイタルケーエスケー・ホールディングス
|
— |
−100%
Exit
—
|
1 | 1,323 | M |
| Portfolio total | 32,650 | 42,545 | |||
Book value in ¥M · ↓ reduced · ↑ increased vs prior year · M = mutual holding